



Introduction

- Nationally, testosterone prescriptions have increased from 7.3 million to more than 11 million between 2019 and 2024. Conservative estimate IQVIA.com
- · Increased awareness
- Fueled the rise of questionable clinics selling testosterone and other treatments as a cure all to those who
 don't need it
- According to the American Urological Association, up to a third of men taking testosterone have never been diagnosed with a deficiency
- 25% of testosterone the rapy patients have never had a serum testosterone level checked before starting treatment
- $\bullet~50\%$ of patients on testosterone the rapy have never had a serum testosterone level checked after starting treatment

Alabama Board of Medical Examiners


New York Times, Jan 25, 2025, American Urologic Association 20





Introduction


Testosterone is a schedule III-controlled substance with the potential to cause significant adverse effects if prescribed for inappropriate indications and without proper medical supervision


Alabama Board of Medical Examine
















Relationship	between	age and	testosterone



Relationship between age, BMI and hormones





Who is a candidate for androgen supplementation?

Men with abnormal testosterone below 300 ng/dl

Confirmed on subsequent AM lab evaluation

Exclusion of other related conditions

Valid symptoms



Valid Symptoms and Low Testosterone < 300 ng/dl

- Persistent fatigue after lifestyle and medical workup
- Decline in muscle mass
- Decline in libido
- Erectile dysfunction
- Depression
- Sleep disturbance
- Idiopathic anemia
- · Persistent sleep disturbance with ongoing treatment for sleep apnea

Alabama Board of Medical Examiners



Evaluation

- History and physical exam including genitourinary
- · Penis, scrotum, testes, prostate
- Breasts
- General body habitus
- Confirmatory laboratory including fasting early morning serum total testosterone, LLH, Hemoglobin, Hematocrit, Prolactin and PSA

Alabama Board of Medical Examiners



Contraindications to Treatment


- Future fertility
- Active prostate cancer
- Uncertain serum PSA status
- Cardiac arrhythmia
- Undiagnosed or unmanaged sleep apnea
- Primary or secondary polycythemia
- Active liver and or gallbladder disease

Alabama Board of Medical Examiner



Counseling on Risks of Testosterone Replacement

- · Loss of testicular volume and function
- Impaired fertility
- Small increase in risk of thrombotic events (cardiac & cerebral)
- Small increase in risk of cardiac arrhythmia
- $\bullet \ \ Significant \ risk \ of secondary \ polycythemia/erethrocytos is$
- · Possible risk of major cardiac or thrombotic event if testosterone levels are too high
- $\bullet\,$ Elevated estrogen levels, gynecomastia and mood alteration
- · Increase in prostate size and lower urinary tract symptoms






Additional Counseling

All men should be counseled on the importance of a high-quality diet, exercise, sleep quality, stress management, avoidance of marijuana and alcohol, and general medical evaluation

Optimizing these variables will often help patients normalize testosterone levels without needing replacement






Origins of Testosterone Replacement Therapy

- $\bullet\,$ First isolated and synthesized in 1935
- Initial formulations had negligible oral bioavailability and a very short duration of action due to extensive hepatic metabolism
- Testosterone therapy has evolved considerably since the days of the 19th century French physiologist Charles Brown-Sequard, who extolled the virtues of a guinea pig testicular extract in restoring waning potency and virility

Alabama Board of Medical Examiners

Hayes, FJ, JCEM 2000,30



7

	3 Month Follow Up Information
Repeat serum test	osterone, hemoglobin, hematocrit and PSA level
Physical exam by	physician
Evaluate response	
If no benefit is cor	nfirmed, testosterone should be discontinued
Consider referral a	at any time to urologist or medical endocrinologist
Adhere to the phil-	osophy of: <u>lowest effective dose</u>
Consider checking	PDMP to identify potential testosterone abuse
	Alabama Board of Medical Examiners
	Ongoing Treatment Follow Up
Die	
Repeat labs every	6 months
-	6 months rone over 800 ng/dl should be considered excessive
Serum testoster	
Serum testoster Consider checking	rone over 800 ng/dl should be considered excessive
Serum testoster Consider checking Refer challenging Patients should be	rone over 800 ng/dl should be considered excessive pDMP at initiation and annually to identify potential testosterone abuse
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive 3 PDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist 2 seen by their physician at least once per year after steady state has been
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive PDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive 3 PDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist 2 seen by their physician at least once per year after steady state has been
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit
Serum testoster Consider checking Refer challenging Patients should be established	rone over 800 ng/dl should be considered excessive RPDMP at initiation and annually to identify potential testosterone abuse patients to a urologist or medical endocrinologist escen by their physician at least once per year after steady state has been of an acceptable visit

 Testosterone replacement therapy is a useful tool in managing the symptomatic testosterone deficient male, but also one that can easily be abused with detrimental health risks to our patients.

Alabama Board of Medical Examiners



Testosterone Therapy for Women

- Current data supports the short-term efficacy and safety of testosterone treatment in post
 menopausal women with sexual dysfunction due to hypoactive sexual desire disorder (HSDD),
 after an evaluation has excluded other causes such as relationship, psychological and
 medication related.
- Limited data supports the use in perimenopausal women.
- $\bullet\,$ Combined hormonal and psychosexual approaches may be beneficial in some cases with mixed etiologies.

Alabama Board of Medical Examiners

NY Times October 22,2025

'I'm on Fire': Testosterone Is Giving Women Back Their Sex Drive — and Then Some Park is no F.D.A. approved instalation or product for women. Insurance word core: A May decides word practicals. It is



Alabama Board of Mudical Evaminary



Changes in Circulating Hormone Levels at Menopause

	Premenopause	Postmenopause
Estradiol	40 – 400 pg/ml	10 – 20 pg/ml
Estrone	30 – 200 pg/ml	30 – 70 pg/ml
Testosterone	20 – 80 pg/ml	15 – 70 pg/ml
Androstenedione	60 – 300 ng/dl	30 – 150 ng/dl

Alabama Board of Medical Examiners Sparoff Cirical Endocrirology and



Hypoactive Sexual Desire Disorder

- Defined as the absence of sexual fantasies and thoughts and/or desire for or receptivity to, sexual activity that causes the personal distress or difficulties in the relationship lasting for at least 6 months.
- Causes can be multifactorial and can include central processes (i.e. neuroendocrine imbalance, medication, hypogonadism, psychological distress) and cultural factors (religious or cultural emphasis on sexual purity).
- Can be associated with profound negative effects on mood, self esteem, and partner relationships and can cause significant decrease in quality of life.

Alabama Board of Medical Examiners

Uloko et al: 2022 J Sexual Med



HSDD Diagnosis and Evaluation

- Use of a validated self report screening and diagnostic instrument
 - Decreased Sexual Desire Screener (Panay N: Sept 2022 Post Reprod Health;28(3):158)
 - Lab evaluation
 - Total serum testosterone
 - $\bullet\,$ Mid to high range level may not need additional supplementation
 - Sex Hormone Binding Globulin
 - Women with levels above normal range are less likely to benefit from testosterone therapy

Alabama Board of Medical Examiners



HSDD Evaluation and Monitoring

Checking a free testosterone may provide an insight into the lack of response in women not
experiencing an improvement of symptoms with testosterone treatment.

Alabama Board of Medical Examiners



When Testosterone Therapy is Not Recommended

- Infertility
- Sexual dysfunction other than HSDD
- Improvement of cardiovascular, metabolic or bone health
- Depression
- · General wellbeing
- Enhance cognitive performance
- Delay cognitive decline
- $\bullet \ \ Treatment \ of low and rogen levels \ due \ to \ hypopituitarism, a drenal insufficiency, surgical menopause, pharmacologic glucocorticoid administration$

Alabama Board of Medical Evaminer



Alabama Board of Medical Examiners



Treatment Methods

Aim for testosterone concentrations in the physiologic postmenopausal range

Consider a trial of conventional hormone replacement therapy first

No FDA approved products for women

When using male approved products use $1/10^{\rm th}$ the recommended starting dose for men

Options: Gel, cream, patch (transference risk)

Not recommended: Testosterone implants, IM injections, oral preparations (includes buccal lozenges and troches) $\,$

Alabama Board of Medical Examine

General Concerns: Safety & Efficacy of Custom Compounded Hormone **Therapy**

- There is a lack of high quality data on the safety and efficacy of custom compounded bioidentical hormone therapy for the management of menopausal symptoms
- Compounded bioidentical menopausal therapy should not be prescribed routinely when FDA approved formulations quiet.
- Due to lack of regulation, the amount of active medication can be highly variable within a specific dose
- . There are no requirements for adverse event reporting, which hinders a definitive evaluation of safety
- Patients requesting the use of compounded bioidentical menopausal hormone therapy should be counseled on the lack of FDA approval of these preparations and their potential risks and benefits

nittee on Clinical Consensus-Gynecology. Compounded Bioidentical Menopausal Hormone Therapy. Obstetrics and Gynecology;142:1266-1273

Alabama Board of Medical Examiners

Testosterone Pellets: Safety Concerns

- The FDA released a letter referencing the lack of reporting of more than 4,200 adverse events, including endometrial cancers, by the BioTE Medical company based in Irving, TX that provides bioidentical hormone pellet therapy
- The global consensus on the use of testosterone in women (which is endorsed by multiple
 international societies) is clear that the use of these pellets does not represent appropriate care
- We have to tell women that their new mustache, deepened voice, or clitoromegaly is permanent

Dunsmoor-Su R. Testosterone Therapy in Women. Obstetrics and Gynecology 2021;138:809-812

Alabama Board of Medical Examin



Duration and Monitoring of Treatment

- Serum testosterone, liver function and fasting lipids should be measured at baseline
- Serum testosterone should be measured 3-6 weeks after treatment has started (levels do not always predict response to therapy)
- Evaluate response at 3 to 6 months after treatment start and then every 6 months
- Discontinue treatment if no response at 6 months

Alabama Board of Medical Examiner



Safety Information

No safety and efficacy data for testosterone therapy available after 24 months Long term effects on cardiovascular risk and breast cancer incidence are not known Women on testosterone therapy should be monitored for signs and symptoms of androgen excess every 6 months

Alabama Board of Medical Evaminer





Conclusions

There has been a marked increase in testosterone utilization in both men and women over the past several years.

Risks have been underappreciated and can be significant

Patients require careful monitoring

Long term impacts of therapy in women are not fully appreciated

Alabama Board of Medical Examiner